Perseus Proteomics Inc. (TYO:4882)

Market Cap	5.90B
Revenue (ttm)	120.38M
Net Income (ttm)	-904.80M
Shares Out	14.75M
EPS (ttm)	-63.41
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	289,000
Average Volume	498,520
Open	402.00
Previous Close	400.00
Day's Range	401.00 - 414.00
52-Week Range	355.00 - 1,113.00
Beta	0.56
RSI	44.66
Earnings Date	Aug 12, 2025

About Perseus Proteomics

Perseus Proteomics Inc., a drug discovery biotech venture company, develops antibody drugs against cancer and other diseases in Japan. The company is involved in the antibody discovery activities; and antibody research support activities comprising hybridoma antibody sequencing, antibody protein production, and contract antibody research activities, as well as supply of antibody products. Its product pipeline includes PPMX-T001, an anti-hepatocarcinoma antibody; PPMX-T002, an anticancer drug; PPMX-T003, a drug for the treatment of adult T-cell;...

• Industry: Drug Manufacturers - General
• Sector: Healthcare
• Founded: 2001
• Employees: 25
• Stock Exchange: Tokyo Stock Exchange
• Ticker Symbol: 4882

Financial Performance

In 2024, Perseus Proteomics's revenue was 120.38 million, an increase of 20.38% compared to the previous year's 100.00 million. Losses were -904.80 million, -18.04% less than in 2023.